Vulcan Value Partners LLC Has $72.85 Million Position in IQVIA Holdings Inc. $IQV

Vulcan Value Partners LLC lowered its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 52.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 323,201 shares of the medical research company’s stock after selling 357,732 shares during the quarter. IQVIA comprises approximately 1.3% of Vulcan Value Partners LLC’s investment portfolio, making the stock its 20th biggest position. Vulcan Value Partners LLC owned about 0.19% of IQVIA worth $72,852,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in IQV. Brighton Jones LLC grew its position in IQVIA by 244.4% during the fourth quarter. Brighton Jones LLC now owns 3,575 shares of the medical research company’s stock worth $703,000 after buying an additional 2,537 shares in the last quarter. Empowered Funds LLC grew its position in IQVIA by 102.1% during the first quarter. Empowered Funds LLC now owns 9,728 shares of the medical research company’s stock worth $1,715,000 after buying an additional 4,915 shares in the last quarter. Sivia Capital Partners LLC acquired a new stake in IQVIA during the second quarter worth approximately $514,000. First Trust Advisors LP grew its position in IQVIA by 14.8% during the second quarter. First Trust Advisors LP now owns 92,015 shares of the medical research company’s stock worth $14,501,000 after buying an additional 11,845 shares in the last quarter. Finally, NewEdge Advisors LLC grew its position in IQVIA by 5.4% during the second quarter. NewEdge Advisors LLC now owns 22,731 shares of the medical research company’s stock worth $3,582,000 after buying an additional 1,155 shares in the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Stock Up 2.5%

Shares of NYSE:IQV opened at $165.97 on Thursday. The firm has a market cap of $27.70 billion, a P/E ratio of 20.57, a P/E/G ratio of 1.55 and a beta of 1.18. The company has a quick ratio of 0.75, a current ratio of 0.75 and a debt-to-equity ratio of 2.20. IQVIA Holdings Inc. has a 12-month low of $136.41 and a 12-month high of $247.04. The business has a fifty day simple moving average of $169.80 and a 200 day simple moving average of $196.48.

IQVIA (NYSE:IQV) last announced its earnings results on Tuesday, May 5th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.83 by $0.07. The business had revenue of $4.15 billion during the quarter, compared to analyst estimates of $4.10 billion. IQVIA had a return on equity of 30.50% and a net margin of 8.33%.IQVIA’s revenue for the quarter was up 8.4% compared to the same quarter last year. During the same period last year, the company earned $2.70 EPS. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. Analysts predict that IQVIA Holdings Inc. will post 11.57 earnings per share for the current year.

IQVIA declared that its board has authorized a stock buyback program on Thursday, May 7th that allows the company to repurchase $2.00 billion in shares. This repurchase authorization allows the medical research company to purchase up to 6.8% of its shares through open market purchases. Shares repurchase programs are often an indication that the company’s management believes its stock is undervalued.

Wall Street Analyst Weigh In

IQV has been the topic of a number of analyst reports. Royal Bank Of Canada initiated coverage on IQVIA in a research report on Tuesday, March 3rd. They set an “outperform” rating and a $221.00 price target on the stock. Mizuho set a $215.00 target price on IQVIA in a report on Monday, February 23rd. Wall Street Zen raised IQVIA from a “hold” rating to a “buy” rating in a report on Sunday, April 19th. Citigroup reduced their target price on IQVIA from $230.00 to $200.00 and set a “neutral” rating on the stock in a report on Friday, February 6th. Finally, Evercore reaffirmed an “outperform” rating and issued a $185.00 target price on shares of IQVIA in a report on Wednesday, April 8th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $225.69.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.